Head-to-head evidence
PF-06410293 vs SAR441566
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
PF-06410293
Marketed by Pfizer
NCT02480153 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled Phase 3 trial in 597 patients comparing PF-06410293 with adalimumab-EU on a hard clinical endpoint: ACR20 response at Week 12. The primary equivalence analysis succeeded, with the 95% confidence interval for the response rate difference falling entirely within the prespecified -14% to +14% margin (observed difference -2.98%, 95% CI -10.38% to 4.44%). The large sample size, blinding, active comparator, and met primary endpoint together provide strong evidence of equivalent efficacy.
SAR441566
Developed by Sanofi
NCT06073093 · Phase 2 · completed
The study randomized 264 participants to four SAR441566 dose regimens or placebo and used triple masking of participants, investigators, and outcome assessors. Its primary endpoint was the clinical ACR20 response at week 12, but results have not been posted, so whether the endpoint was met or missed cannot be assessed.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PF-06410293's landscape · SAR441566's landscape